Developer docs
API playgroundTry for free, no card

Search company profiles

Karo Pharma

Full company profile

uuid02lkmv2

Namestring
Karo Pharma
Legal namestring
Karo Healthcare AB
Websiteurl
karopharma.com
Company typeenum
Private
Founded yearint
1987
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
consumer healthcare products, over-the-counter medicines, dermatology skincare brands, vitamins mineral supplements, intimate digestive health
Industry4 codes
PRIMARYCRAOAHAB
OTC Medicines & Consumer Health Products Distribution
SECONDARYCRAFAFAI
Pharmacy & Health Essentials Delivery
Consumer Products & Retail/E-commerce & Marketplaces/Grocery & On-demand Delivery Commerce
SECONDARYCRAFADAG
Health, Wellness & Pharmacy Online Retailers
Consumer Products & Retail/E-commerce & Marketplaces/Online Retailers (Inventory-led)
SECONDARYCRADAGAB
Vitamins & Minerals (Single Nutrients)
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Pharmacies and Drug Retailers45611
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Consumer Healthcare (OTC)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1OTC Consumer Healthcare Products
TypeOne Time License
Description

Sale of branded, original over-the-counter (OTC) products within everyday healthcare categories including skin health, intimate health, digestive health, foot health, and vitamins and mineral supplements.

karohealthcare.com
2Prescription Medicines
TypeOne Time License
Description

Commercialisation of prescription drugs alongside OTC products, though focus has shifted primarily to consumer healthcare.

karohealthcare.com
3Digital Commerce and E-commerce
TypeTransaction Fee
Description

Products sold through digital-first brands on Amazon, e-pharmacies and direct-to-consumer channels through Sylphar platform.

karohealthcare.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Marketing or Sales, Supply Chain, Personnel, Technology or R&D, Operations, Others
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 12 records shown
1Proct
Description

Digestive Health brand

karohealthcare.com
+11 more records
Core offering1 text field

Karo Pharma develops, acquires and commercialises a portfolio of branded, original over-the-counter (OTC) consumer healthcare products and medicines across categories including skin health (E45, Remescar, Decubal, Locobase), intimate health (Multi-Gyn, Pevaryl), digestive health (Proct), foot health (Lamisil), oral health (Flux, Fludent, iWhite), pain relief (Paracet), and vitamins & mineral supplements (Nutravita, Alpha Foods, Lactocare). Products are sold under both legacy Karo brand sites and via in-house e-commerce, distributed across pharmacies, physical retail, and digital channels in 90+ countries with Europe and the Nordic region as core markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Revenue exceeding €500 million
+2 more records
Product overview1 text field

Karo Healthcare operates as a consumer healthcare company with a diversified portfolio of over-the-counter (OTC) medicines, medical devices, and nutritional supplements. The company's product offering consists of multiple acquired consumer health brands organized by therapeutic categories including skin health (E45, Decubal, Apobase, Locobase), foot health (Lamisil, Pevaryl), digestive health (Proct), intimate health (Multi-Gyn), oral care (Flux, Fludent, iWhite), pain relief (Paracet), and vitamins/supplements (Nutravita, Alpha Foods, Lactocare). The portfolio was built through strategic acquisitions, including the Teva portfolio, Sylphar International NV, E45 from Reckitt, and Lamisil from Haleon.

Product and service21 records
1E45
CategorySkin Health / Dermatology
Description

A well-established dermatological skincare brand used for dry skin, eczema, and related skin conditions; sold to consumers across Europe and other markets via pharmacies, retail and e-commerce.

2Lamisil
CategoryFoot Health / Antifungal
Description

Widely recognised over-the-counter treatment for fungal nail and skin infections, sold to consumers in foot health category across multiple markets.

3Proct
CategoryDigestive Health
Description

Digestive health brand addressing hemorrhoid and anal discomfort treatments for self-care consumers.

4Nutravita
CategoryVitamins & Mineral Supplements (VMS)
Description

Vitamins and mineral supplements brand sold primarily via Amazon, e-pharmacies and other digital channels to consumers across more than 50 countries.

5Multi-Gyn
CategoryIntimate Health
Description

Intimate health brand addressing women's vaginal and intimate care needs with probiotic-based products.

6Pevaryl
CategoryFoot Health / Antifungal
Description

Antifungal OTC brand for skin and nail conditions, distributed across European markets.

7Remescar
CategorySkin Health / Dermatology
Description

Skincare brand offering corrective and instant visible skincare solutions for dermatological needs.

8Flux
CategoryOral Health
Description

Oral care brand addressing dental care needs of consumers.

9Paracet
CategoryPain Relief
Description

Pain relief medication brand for mild to moderate pain, used by consumers across multiple markets.

10Decubal
CategorySkin Health / Dermatology
Description

Dermatological skincare brand acquired from Teva, used for dry skin and skin barrier care.

11Alpha Foods
CategoryVitamins & Mineral Supplements (VMS)
Description

Nutritional supplements brand focused on vegan lifestyle and superfood products.

12Locobase
CategorySkin Health / Dermatology
Description

Dermatological skincare brand in the Karo Healthcare portfolio, supporting skin barrier care for consumers.

13Satin Naturel
CategorySkin Health / Natural Cosmetics
Description

Natural cosmetics / aloe vera product portfolio brand acquired through Sylphar.

14MOB-015 (Europe)
CategorySkin Health / Dermatology
Description

Exclusive European licence for MOB-015 from Moberg Pharma AB, expanding Karo's portfolio within the dermatology/skin health category.

15Lactocare
CategoryVitamins & Mineral Supplements (VMS)
Description

Probiotic supplement brand acquired as part of the Teva portfolio.

16Apobase
CategorySkin Health / Dermatology
Description

Dermatological skincare brand included in the Teva portfolio acquisition.

17Dailycare
CategoryPersonal Care
Description

Personal care brand from the Teva portfolio.

18Fludent
CategoryOral Health
Description

Oral care products acquired as part of the Teva portfolio.

19iWhite
CategoryOral Health / Cosmetics
Description

Teeth whitening brand in the consumer health portfolio.

20E45 brand (Reckitt acquisition)
CategorySkin Health / Dermatology
Description

Dermatology brand E45 brought in through the GBP 200m acquisition from Reckitt, supporting the skin health portfolio.

21Sylphar International NV (digital-first platform)
CategoryDigital Commerce Platform
Description

Belgium-based digital-first consumer health and beauty platform with brands sold through online marketplaces, web shops and e-pharmacies in more than 50 countries; provides digital commerce capabilities for Karo.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-08-14
Description

Digital-first platform acquired in January 2022 for EUR 290m, bringing cutting-edge e-commerce and digital marketing capabilities. Sylphar is a Belgium-based fast-growing consumer health and beauty platform with brands sold through online marketplaces, web shops and e-pharmacies in more than 50 countries.

2Moberg Pharma
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-05
Description

Exclusive license agreement for MOB-015 in Europe, expanding Karo's portfolio within the dermatology/skin health category.

karohealthcare.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Charitable partnership supporting Operation Smile since 2018. Every three minutes, a child with cleft lip or palate is born, and Operation Smile performs about 15,000 surgeries per year. Karo supports this initiative as part of its smart choices for everyday healthcare commitment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Signatory since 2022 to the world's largest corporate sustainability initiative.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Near-term and net-zero targets validated by the Science Based Targets initiative, supporting Karo's climate ambition aligned with 1.5°C pathway.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Member since 2022, promoting responsible supply chain standards and continuous improvement.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Reports climate performance transparently, achieved B score in 2025.

8Roundtable on Sustainable Palm Oil (RSPO)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Member supporting responsible sourcing of palm oil through Certified Sustainable Palm Oil credits.

karohealthcare.com
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German-based PE-owned (Cinven) pharmaceutical company with significant consumer healthcare and OTC portfolio across Europe, including dermatology, cold/flu and women's health. Direct comparable as a mid-cap European OTC brand aggregator that has executed a similar M&A-driven growth playbook.

TypeBroad incumbent
Description

Global OTC consumer healthcare leader (spun off from GSK) owning brands like Voltaren, Centrum, Advil, Sensodyne. Comparable as a major incumbent OTC player from which Karo acquired Lamisil in 2023; overlaps in foot health, oral health, VMS and pain relief categories.

TypeDirect peer
Description

Global dermatology-focused pharmaceutical company (owned by Nestlé and EQT) with significant OTC and prescription skin health products. Comparable in skin-health category depth (E45, Lamisil, Decubal, Locobase, Remescar) and similar EQT-private-equity ownership heritage.

4Bayer Consumer Health
TypeBroad incumbent
Description

Division of Bayer AG focused on OTC self-care products across categories where Karo competes (digestive health, skin care, foot health). Karo acquired Proctosedyl rights from Bayer in 2024; comparable as a major incumbent divesting non-core OTC assets.

TypeBroad incumbent
Description

Global consumer healthcare and hygiene major (Dettol, Nurofen, Gaviscon, Durex). Karo acquired E45 from Reckitt in 2022; comparable as a large incumbent divesting non-core consumer health brands that Karo specialises in absorbing and operating at mid-cap scale.

TypeDirect peer
Description

Swedish-based consumer healthcare company with overlapping Nordic presence and similar OTC brand portfolio focus. Several Karo senior leaders (COO Jonathan Kimber, CSAO Sofia Kyhlstedt) previously worked at Trimb, indicating direct operational and strategic parallels.

TypeBroad incumbent
Description

Global nutrition, supplements and consumer health business of Nestlé focused on VMS, medical nutrition and preventive health. Comparable for VMS overlap (Nutravita, Alpha Foods, Lactocare) and parent-company dynamics similar to Karo's relationship with major strategic owners.

TypeDirect peer
Description

Spanish-listed pharmaceutical company with strong dermatology and skin-health OTC focus across Europe. Comparable for portfolio overlap in skin health (E45, Decubal, Locobase, Remescar) and similar Southern European commercial footprint strategy.

TypeBroad incumbent
Description

US-listed consumer products company with growing health and wellness portfolio (Batiste, OxiClean, Trojan, First Response). Comparable as a brand-aggregator consumer health operator with similar multi-category branded portfolio model and disciplined acquisition approach.

TypeDirect peer
Description

US-listed OTC consumer healthcare company focused on store-brand and branded self-care products across skin, digestive, foot health and oral care. Comparable as a similarly diversified European-exposed OTC brand operator competing for the same retailer shelf space and brand divestitures from major pharma.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries10 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Karo Pharma

Consumer Healthcare (OTC)karopharma.com

Karo Pharma firmographics

Firmographics
Name
Karo Pharma
Legal name
Karo Healthcare AB
Website
https://karopharma.com
Company type
Private
Founded year
1987
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Karo Pharma industry classification

Industry
Product category
Consumer Healthcare (OTC)
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmacies and Drug Retailers (45611)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRAOAHAB
OTC Medicines & Consumer Health Products Distribution
SECONDARYCRAFAFAI
Pharmacy & Health Essentials Delivery
Consumer Products & Retail/E-commerce & Marketplaces/Grocery & On-demand Delivery Commerce
SECONDARYCRAFADAG
Health, Wellness & Pharmacy Online Retailers
Consumer Products & Retail/E-commerce & Marketplaces/Online Retailers (Inventory-led)
SECONDARYCRADAGAB
Vitamins & Minerals (Single Nutrients)

Keywords

  • Consumer healthcare products
  • Over-the-counter medicines
  • Dermatology skincare brands
  • Vitamins mineral supplements
  • Intimate digestive health

Where Karo Pharma is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices4 records

Markets served

Karo Pharma business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Marketing or Sales, Supply Chain, Personnel, Technology or R&D, Operations, Others

Revenue model

  1. OTC Consumer Healthcare Products: Sale of branded, original over-the-counter (OTC) products within everyday healthcare categories including skin health, intimate health, digestive health, foot health, and vitamins and mineral supplements.
  2. Prescription Medicines: Commercialisation of prescription drugs alongside OTC products, though focus has shifted primarily to consumer healthcare.
  3. Digital Commerce and E-commerce: Products sold through digital-first brands on Amazon, e-pharmacies and direct-to-consumer channels through Sylphar platform.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Karo Pharma product offering

Product offering

Core offering

Karo Pharma develops, acquires and commercialises a portfolio of branded, original over-the-counter (OTC) consumer healthcare products and medicines across categories including skin health (E45, Remescar, Decubal, Locobase), intimate health (Multi-Gyn, Pevaryl), digestive health (Proct), foot health (Lamisil), oral health (Flux, Fludent, iWhite), pain relief (Paracet), and vitamins & mineral supplements (Nutravita, Alpha Foods, Lactocare). Products are sold under both legacy Karo brand sites and via in-house e-commerce, distributed across pharmacies, physical retail, and digital channels in 90+ countries with Europe and the Nordic region as core markets.

Product overview

Karo Healthcare operates as a consumer healthcare company with a diversified portfolio of over-the-counter (OTC) medicines, medical devices, and nutritional supplements. The company's product offering consists of multiple acquired consumer health brands organized by therapeutic categories including skin health (E45, Decubal, Apobase, Locobase), foot health (Lamisil, Pevaryl), digestive health (Proct), intimate health (Multi-Gyn), oral care (Flux, Fludent, iWhite), pain relief (Paracet), and vitamins/supplements (Nutravita, Alpha Foods, Lactocare). The portfolio was built through strategic acquisitions, including the Teva portfolio, Sylphar International NV, E45 from Reckitt, and Lamisil from Haleon.

Differentiator

Problem solved

Functional benefit

Brands

  • Proct: Digestive Health brand
  • Lamisil
  • E45
  • Nutravita
  • Remescar
  • Pevaryl
  • Flux
  • Multi-Gyn
  • Paracet
  • Alpha Foods
  • Decubal
  • Locobase

Products and services

  • E45 A well-established dermatological skincare brand used for dry skin, eczema, and related skin conditions; sold to consumers across Europe and other markets via pharmacies, retail and e-commerce.
  • Lamisil Widely recognised over-the-counter treatment for fungal nail and skin infections, sold to consumers in foot health category across multiple markets.
  • Proct Digestive health brand addressing hemorrhoid and anal discomfort treatments for self-care consumers.
  • Nutravita Vitamins and mineral supplements brand sold primarily via Amazon, e-pharmacies and other digital channels to consumers across more than 50 countries.
  • Multi-Gyn Intimate health brand addressing women's vaginal and intimate care needs with probiotic-based products.
  • Pevaryl Antifungal OTC brand for skin and nail conditions, distributed across European markets.
  • Remescar Skincare brand offering corrective and instant visible skincare solutions for dermatological needs.
  • Flux Oral care brand addressing dental care needs of consumers.
  • Paracet Pain relief medication brand for mild to moderate pain, used by consumers across multiple markets.
  • Decubal Dermatological skincare brand acquired from Teva, used for dry skin and skin barrier care.
  • Alpha Foods Nutritional supplements brand focused on vegan lifestyle and superfood products.
  • Locobase Dermatological skincare brand in the Karo Healthcare portfolio, supporting skin barrier care for consumers.
  • Satin Naturel Natural cosmetics / aloe vera product portfolio brand acquired through Sylphar.
  • MOB-015 (Europe) Exclusive European licence for MOB-015 from Moberg Pharma AB, expanding Karo's portfolio within the dermatology/skin health category.
  • Lactocare Probiotic supplement brand acquired as part of the Teva portfolio.
  • Apobase Dermatological skincare brand included in the Teva portfolio acquisition.
  • Dailycare Personal care brand from the Teva portfolio.
  • Fludent Oral care products acquired as part of the Teva portfolio.
  • iWhite Teeth whitening brand in the consumer health portfolio.
  • E45 brand (Reckitt acquisition) Dermatology brand E45 brought in through the GBP 200m acquisition from Reckitt, supporting the skin health portfolio.
  • Sylphar International NV (digital-first platform) Belgium-based digital-first consumer health and beauty platform with brands sold through online marketplaces, web shops and e-pharmacies in more than 50 countries; provides digital commerce capabilities for Karo.

Quantifiable outcome

  • Revenue exceeding €500 million
  • +2 more outcomes

Companies that use Karo Pharma

Customer profile

Named customers2 records

Segments7 records

Ideal customer profiles2 records

Karo Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Karo Pharma partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Sylphar NVcoreStrategic or Co-development Partner · 14 August 2026Digital-first platform acquired in January 2022 for EUR 290m, bringing cutting-edge e-commerce and digital marketing capabilities. Sylphar is a Belgium-based fast-growing consumer health and beauty platform with brands sold through online marketplaces, web shops and e-pharmacies in more than 50 countries.
  • Moberg PharmacoreOEM/ Whitelabel/ Licensing Partner · 5 November 2025Exclusive license agreement for MOB-015 in Europe, expanding Karo's portfolio within the dermatology/skin health category.
  • Operation SmileminorStrategic or Co-development PartnerCharitable partnership supporting Operation Smile since 2018. Every three minutes, a child with cleft lip or palate is born, and Operation Smile performs about 15,000 surgeries per year. Karo supports this initiative as part of its smart choices for everyday healthcare commitment.
  • United Nations Global CompactcoreStrategic or Co-development PartnerSignatory since 2022 to the world's largest corporate sustainability initiative.
  • Science Based Targets initiative (SBTi)coreStrategic or Co-development PartnerNear-term and net-zero targets validated by the Science Based Targets initiative, supporting Karo's climate ambition aligned with 1.5°C pathway.
  • Pharmaceutical Supply Chain Initiative (PSCI)coreStrategic or Co-development PartnerMember since 2022, promoting responsible supply chain standards and continuous improvement.
  • CDP (Carbon Disclosure Project)coreStrategic or Co-development PartnerReports climate performance transparently, achieved B score in 2025.
  • Roundtable on Sustainable Palm Oil (RSPO)coreStrategic or Co-development PartnerMember supporting responsible sourcing of palm oil through Certified Sustainable Palm Oil credits.

Scale indicators11 records

Recent moves11 records

Expansion highlights6 records

Karo Pharma competitors and assessment

Company assessment

Direct peers

  • Stada Arzneimittel: German-based PE-owned (Cinven) pharmaceutical company with significant consumer healthcare and OTC portfolio across Europe, including dermatology, cold/flu and women's health. Direct comparable as a mid-cap European OTC brand aggregator that has executed a similar M&A-driven growth playbook.
  • Galderma: Global dermatology-focused pharmaceutical company (owned by Nestlé and EQT) with significant OTC and prescription skin health products. Comparable in skin-health category depth (E45, Lamisil, Decubal, Locobase, Remescar) and similar EQT-private-equity ownership heritage.
  • Trimb Healthcare: Swedish-based consumer healthcare company with overlapping Nordic presence and similar OTC brand portfolio focus. Several Karo senior leaders (COO Jonathan Kimber, CSAO Sofia Kyhlstedt) previously worked at Trimb, indicating direct operational and strategic parallels.
  • Almirall: Spanish-listed pharmaceutical company with strong dermatology and skin-health OTC focus across Europe. Comparable for portfolio overlap in skin health (E45, Decubal, Locobase, Remescar) and similar Southern European commercial footprint strategy.
  • Perrigo Company: US-listed OTC consumer healthcare company focused on store-brand and branded self-care products across skin, digestive, foot health and oral care. Comparable as a similarly diversified European-exposed OTC brand operator competing for the same retailer shelf space and brand divestitures from major pharma.

Broad incumbents

  • Haleon: Global OTC consumer healthcare leader (spun off from GSK) owning brands like Voltaren, Centrum, Advil, Sensodyne. Comparable as a major incumbent OTC player from which Karo acquired Lamisil in 2023; overlaps in foot health, oral health, VMS and pain relief categories.
  • Bayer Consumer Health: Division of Bayer AG focused on OTC self-care products across categories where Karo competes (digestive health, skin care, foot health). Karo acquired Proctosedyl rights from Bayer in 2024; comparable as a major incumbent divesting non-core OTC assets.
  • Reckitt Benckiser: Global consumer healthcare and hygiene major (Dettol, Nurofen, Gaviscon, Durex). Karo acquired E45 from Reckitt in 2022; comparable as a large incumbent divesting non-core consumer health brands that Karo specialises in absorbing and operating at mid-cap scale.
  • Nestlé Health Science: Global nutrition, supplements and consumer health business of Nestlé focused on VMS, medical nutrition and preventive health. Comparable for VMS overlap (Nutravita, Alpha Foods, Lactocare) and parent-company dynamics similar to Karo's relationship with major strategic owners.
  • Church & Dwight: US-listed consumer products company with growing health and wellness portfolio (Batiste, OxiClean, Trojan, First Response). Comparable as a brand-aggregator consumer health operator with similar multi-category branded portfolio model and disciplined acquisition approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Karo Pharma social profiles

Digital presence

Karo Pharma compliance and trust

Trust signal

Compliance5 records

Karo Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Karo Pharma leadership team

Management profile

Number of profiles

Profiles11 records

Karo Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries10 records

Karo Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Karo Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karo Pharma

What does Karo Pharma do?

Karo Pharma develops, acquires and commercialises a portfolio of branded, original over-the-counter (OTC) consumer healthcare products and medicines across categories including skin health (E45, Remescar, Decubal, Locobase), intimate health (Multi-Gyn, Pevaryl), digestive health (Proct), foot health (Lamisil), oral health (Flux, Fludent, iWhite), pain relief (Paracet), and vitamins & mineral supplements (Nutravita, Alpha Foods, Lactocare). Products are sold under both legacy Karo brand sites and via in-house e-commerce, distributed across pharmacies, physical retail, and digital channels in 90+ countries with Europe and the Nordic region as core markets.

Is Karo Pharma a public or private company?

Karo Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was Karo Pharma founded?

Karo Pharma was founded in 1987. It employs 251 to 500 people.

Where is Karo Pharma based?

Karo Pharma is headquartered in Stockholm, Sweden, in the Europe region.

How does Karo Pharma make money?

Three revenue lines are on record. OTC Consumer Healthcare Products are the primary driver. The others are prescription Medicines and digital Commerce and E-commerce.

Who are Karo Pharma's main competitors?

Direct peers on record are Stada Arzneimittel, Galderma, Trimb Healthcare, Almirall and Perrigo Company. Broad incumbents are Haleon, Bayer Consumer Health, Reckitt Benckiser, Nestlé Health Science and Church & Dwight.

Does Karo Pharma have an API?

No public API is recorded for Karo Pharma.

What industry is Karo Pharma in?

Karo Pharma's product category is Consumer Healthcare (OTC). Its primary akta.pro industry code is CRAOAHAB, OTC Medicines & Consumer Health Products Distribution, with a secondary code of CRAFAFAI, Pharmacy & Health Essentials Delivery. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Osborne Clarke International Legal PracticeOsborne Clarke advises Sylphar NV and Karo Pharma AB on purchase of Satin NaturelSylphar NV and Karo Pharma AB have acquired the Satin Naturel business from Del Decus Enterprises Ltd, a move advised by Osborne Clarke. The transaction includes Satin Naturel's aloe vera product portfolio, trademarks, Amazon accounts, and key management personnel. This acquisition aligns with Karo Pharma's strategy to expand its consumer health brands through its digital-first platform Sylphar.Cosmetics BusinessKaro Pharma acquisition will drive E45 omnichannel switch, says Swedish firmKaro Pharma will acquire dermatology brand E45 from Reckitt for £200m, expected to close in Q2 2022. E45 had £43m annual net sales in 2021 and is market-leading in the UK and South Africa. The deal aims to shift E45 to omnichannel, leveraging Karo's Sylphar e-commerce capabilities.news.cision.comKaro Intressenter AB announces final outcome of the public cash offer to the shareholders in Karo Pharma AktiebolagKaro Intressenter completed its public cash offer for Karo Pharma, acquiring 97% of shares and initiating compulsory redemption of the remainder. The company's shares will be delisted from Nasdaq First North Growth Market, with the last trading day set for 24 November 2022.PR NewswireKaro Pharma Aktiebolag's application for de-listing has been approvedKaro Pharma Aktiebolag's application to de-list from Nasdaq First North Growth Market has been approved by Nasdaq. The exchange has resolved that the last day of trading in Karo Pharma shares will be 24 November 2022. This voluntary de-listing marks the company's exit from public trading on the Swedish growth market.PR NewswireKaro Pharma Aktiebolag applies for de-listingKaro Pharma Aktiebolag's Board of Directors has resolved to apply for de-listing of the Company's shares from Nasdaq First North Growth Market, following Karo Intressenter AB's acquisition of 96.8 percent of shares and subsequent initiation of compulsory redemption of remaining shares. Karo Intressenter had offered SEK 60 per share in a public cash offer that was declared unconditional on 19 September 2022 and completed, ultimately achieving over 90 percent acceptance. The de-listing request was made at Karo Intressenter's request, with the last trading date to be announced pending confirmation from Nasdaq.news.cision.comKaro Pharma publishes the 2021 annual reportKaro Pharma published its 2021 annual report on its website on 12 April 2022. The report is available in Swedish and English, with Swedish as the original version. The information was submitted for publication on that date at 16:00 CET.news.cision.comKaro Pharma enters into an agreement for the potential acquisition of the E45® brand from ReckittKaro Pharma has entered into a put option agreement to potentially acquire the E45® dermatology brand from Reckitt for a total consideration of GBP 200 million. The transaction, expected to close in the second quarter of 2022, will transfer ownership of the brand, which had estimated net sales of GBP 43 million in 2021, to Karo. This acquisition aims to scale Karo's operations in the UK and strengthen its position in the European dermatology market.news.cision.comKaro Pharma AB divests its Hospital Supply business, Swereco AB, to J2L Holding ABKaro Pharma divested its Hospital Supply business, Swereco, to J2L Holding AB. J2L will acquire all shares for SEK 150 million on a cash and debt-free basis, an EV/EBITDA multiple of 8.5x. The transaction is expected to close on 1 December 2020.PR NewswireKaro Pharma To Acquire Trimb Healthcare from Avista Capital PartnersKaro Pharma AB has signed a definitive agreement to acquire Trimb Healthcare from Avista Capital Partners for approximately SEK 3.4 billion, subject to customary competition authority review and expected to close later in 2019. Trimb is a Stockholm-based consumer healthcare company founded in 2012 with approximately 90 employees, holding licenses to market and sell over-the-counter pharmaceuticals and consumer healthcare products across skin care, foot care, oral care, and intimate health categories. Karo Pharma stated the acquisition complements its business in geographical presence, distribution channels, and product offerings, as Trimb has built a Nordic business and growing Northern European presence.GlobeNewswireDerivatives: Anticipated adjustment in Karo Pharma due to offer (01/19)EQT VIII AB announced a voluntary cash offer to acquire all outstanding shares of Karo Pharma, paying SEK 38 per share, an increase from SEK 36.90. If Karo Pharma requests de-listing or trading is insufficient, NASDAQ Derivatives Markets will adjust options and forwards/futures to fair value, using fixed historic volatility and dividend estimates.